James Chambers
Publications and Insights
- Insight: The Trump Administration’s US Drug Pricing Proposal – What will happen next?
- Publication: Taking STRIDES: The value of diagnostics against AMR
- Insight: Pharmacogenomics Testing: A Crucial Piece to Unlocking the Full Value of Medicines
- Publication: Altering the trajectory of HIV in Europe
- Publication: Challenges and Solutions for Budget Impact Analysis of Gene Therapies
- Insight: Advancing Rare Disease Care: Challenges and Key Issues
- Publication: The Importance of Diversity of Supply in Rare Diseases Markets
- Publication: Employer Costs from Respiratory Infections
- Insight: What is the impact of Uniform Pricing, Indication-Based Pricing (IBP) and alternative commercial arrangements for new pharmaceuticals in the UK NHS?
- Publication: The Cost of Drug Shortages
- Insight: Drug shortages are on the rise – but what is their impact?
- Insight: R&D for new drugs to tackle AMR is a high-return investment for all EU member states
- Publication: A Framework for Value-aligned Pricing of Combination Therapies
- Insight: Using Target Product Profiles (TPPs) to improve diagnostic testing for cancer
- Insight: Plan For A New EU Pharmaceutical Legislation: What Will It Mean For Pharmaceutical Innovation?
- Insight: Rare Disease Day 2024: Why Do We Care About Rare?
- Insight: Navigating the Intersection of Healthcare and Environmental Sustainability: ISPOR Europe round-up on the inclusion of environmental impact in HTA
- Insight: Breaking the European Deadlock: Part 3 – Revenue Guarantee and Subscription Models for New Antibiotics
- Publication: The Dynamics of Drug Shortages
- Insight: Breaking the European Deadlock: Part 2 – Transferable Exclusivity Vouchers – Effective Pull Incentive or a Policy Distraction?
- Insight: The Inflation Reduction Act: Price negotiation underway for the first 10 drugs
- Publication: Capturing the Broader Value of Antibiotics
- Insight: OHE’s AMR consultation response
- Publication: Proposals for a Novel UK Antimicrobial Subscription Model: How Will Antibiotic Innovation be Scored?
- Publication: Proposals for a Novel UK Antimicrobial Subscription Model: The Investor Perspective
- Bulletin: Unlocking prevention for a healthier society
- Publication: Reimagining Prevention for a Healthier, More Prosperous Society
- Publication: Are Recommendations for HTA of Gene Therapies Being Achieved?
- Insight: New Drugs to Tackle Antimicrobial Resistance: Breaking the European Deadlock: Part 1 – Defining Objectives
- Bulletin: The Inflation Reduction Act has landed
- Insight: The US Inflation Reduction Act: What Do the Experts Think?
- Publication: Real-World Evidence: Current Best Practice for Reimbursement Decision-Making
- Publication: Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechanism
- Publication: Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?
- Publication: Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations
- Publication: Payment Models for Multi-Indication Therapies
- Publication: The Lower Drug Costs Now Act and Pharmaceutical Innovation
- Publication: Key Considerations for Early Access Schemes for Single-Administration (One-Time) Therapies
- Publication: Exploring the Financial Sustainability of Gene Therapies
- New: Opportunities to Increase Efficiency in Healthcare
- Publication: Opportunities to Increase Efficiency in Healthcare
- Publication: NICE ‘Optimised’ Decisions: What is the Recommended Level of Patient Access?
- Publication: Indication-Based Pricing (IBP) Consultation Report
- Publication: HTA and Payment Mechanisms for New Drugs to Tackle AMR
- Publication: Documento de debate sobre la fijación de precios en función de la indicación (IBP) ¿Deben variar los precios de los medicamentos según la indicación?
- Publication: Indication-Based Pricing (IBP) Discussion Paper: Should drug prices differ by indication?
- Publication: Value, Access, and Incentives for Innovation: Policy Perspectives on Alternative Models for Pharmaceutical Rebates
- Publication: Making Outcome-Based Payment a Reality in the NHS
- Publication: Public Preferences for Health Gains and Cures: A Discrete Choice Experiment
- Publication: Legal Barriers to the Better Use of Health Data to Deliver Pharmaceutical Innovation
- Publication: Economics of Innovative Payment Models Compared with Single Pricing of Pharmaceuticals
- Publication: The Debate on Indication-Based Pricing in the U.S. and Five Major European Countries
- Publication: Understanding the Context, Selecting the Standards: A Framework to Guide the Optimal Development and Use of Real-World Evidence for Coverage and Formulary Decisions
- Publication: Barriers to Uptake of Minimal Access Surgery in the United Kingdom
- Publication: Public Health and Economic Implications of the United Kingdom Exiting the EU and the Single Market
- Publication: Data Governance Arrangements for Real-World Evidence: South Korea
- Publication: ‘Macro’ Evaluation of the NIHR Oxford Biomedical Research Centre
- Publication: Transferability of HTA
- Publication: How can HTA meet the needs of health system and government decision makers?
- Publication: Assessing Value, Budget Impact and Affordability to Inform Discussions on Access and Reimbursement: Principles and Practice, with Special Reference to High Cost Technologies
- Publication: Gene Therapy: Understanding the Science, Assessing the Evidence, and Paying for Value
- Publication: Exploring the Assessment and Appraisal of Regenerative Medicines and Cell Therapy Products: Is the NICE Approach Fit for Purpose?
- Publication: An Analysis of NICE Technology Appraisal Decisions ‘Recommended in Line with Clinical Practice’
- Publication: Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
- Publication: Four Case Studies to Explore the Added Value of Oxford AHSN
- Publication: Improving Efficiency and Resource Allocation in Future Cancer Care
- Publication: “New Age” Decision Making in HTA: Is It Applicable in Asia?
- Publication: How Can Health Technology Assessments in the Asia-Pacific Area Respond to Increased Clinical Uncertainty as a Consequence of Expedited US and EU Regulatory Processes?
- Publication: A Review of NICE Methods Across Health Technology Assessment Programmes: Differences, Justifications and Implications
- Publication: Data Governance Arrangements for Real-World Evidence
- Publication: Dementia: The R&D Landscape
- Publication: Assessing the Use of Multi-indication Medicines: A Review of Current Data Capabilities in the UK
- Publication: Do Respondents Completing Abstract, Hypothetical Priority-setting Exercises Agree With the Policy Implications of Their Choices?
- Publication: Can the US Afford to Ignore Cost-effectiveness Evidence?